Trials / NCT05282953
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Completed Phase 1 / Phase 2 Optogenetics
- Sponsor
- Kiora Pharmaceuticals, Inc.
- Treatment
- KIO-301
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Choroideremia, Non-Syndromic Rod-Dominant Inherited Retinal Diseases
- Ages
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Started
- 2022-11-10
- Main results expected
- 2023-08-10
- Results posted
- Not yet
- Record last updated
- 2026-05-04
What the study is testing
A phase I/II dose-escalating study of the safety, tolerability and efficacy of KIO-301 administered intravitreally to patients with retinitis pigmentosa and choroideremia (ABACUS).
Where it runs
Australia (3)
- Save Sight Institute, Sydney, New South Wales
- Royal Adelaide Hospital, Adelaide, South Australia
- Harley Eye Clinic, North Adelaide, South Australia